Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)
Devorah R Wieder, Lynn Pattimakiel
Center for Specialized Women’s Health, Ob/Gyn and Women’s Health Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
Abstract: The contraceptive vaginal ring is a novel contraceptive method that offers unique advantages. Intravaginal delivery of both estrogen and progesterone allows continuous release of medication, resulting in lower systemic levels. The use of long-term combined hormonal contraception enables improved cycle control compared with progesterone-only methods. The indications and usage of the NuvaRing® are described along with the efficacy, tolerability, and safety. Overall, the contraceptive vaginal ring appears to be very effective, with a favorable side-effect profile, and is highly acceptable to most patients.
Keywords: vaginal contraception, vaginal ring, hormonal contraception, contraceptive agents, contraceptive device, etonogestrel, ethinyl estradiol, NuvaRing
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.